Concord Biotech Past Earnings Performance
Past criteria checks 6/6
Concord Biotech has been growing earnings at an average annual rate of 12.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 16% per year. Concord Biotech's return on equity is 22.5%, and it has net margins of 31.4%.
Key information
12.8%
Earnings growth rate
12.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.0% |
| Return on equity | 22.5% |
| Net Margin | 31.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Concord Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9,706 | 3,046 | 1,178 | 0 |
| 30 Sep 23 | 9,704 | 3,044 | 1,147 | 0 |
| 30 Jun 23 | 8,670 | 2,453 | 1,134 | 0 |
| 31 Mar 23 | 8,532 | 2,401 | 1,103 | 0 |
| 31 Mar 22 | 7,129 | 1,749 | 957 | 0 |
| 31 Mar 21 | 6,169 | 2,349 | 700 | 0 |
| 31 Mar 20 | 5,123 | 1,691 | 624 | 0 |
Quality Earnings: CONCORDBIO has high quality earnings.
Growing Profit Margin: CONCORDBIO's current net profit margins (31.4%) are higher than last year (27.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CONCORDBIO's earnings have grown by 12.8% per year over the past 5 years.
Accelerating Growth: CONCORDBIO's earnings growth over the past year (36%) exceeds its 5-year average (12.8% per year).
Earnings vs Industry: CONCORDBIO earnings growth over the past year (36%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: CONCORDBIO's Return on Equity (22.5%) is considered high.